Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary aim of this retrospective, multicenter study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Rohini, Pillai, Anjana, Marron, Thomas Urban, Fessas, Petros, Saeed, Anwaar, Jun, Tomi, Dharmapuri, Sirish, Szafron, David, Naqash, Abdul Rafeh, Gampa, Anuhya, Wang, Yinghong, Khan, Uqba, Muzaffar, Mahvish, Lee, Chieh‐Ju, Lee, Pei‐Chang, Bulumulle, Anushi, Paul, Sonal, Bettinger, Dominic, Hildebrand, Hannah, Yehia, Mohammed, Pressiani, Tiziana, Kaseb, Ahmed, Huang, Yi‐Hsiang, Ang, Celina, Kudo, Masatoshi, Nishida, Naoshi, Personeni, Nicola, Rimassa, Lorenza, Pinato, David James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234627/
https://www.ncbi.nlm.nih.gov/pubmed/35481940
http://dx.doi.org/10.1002/hep4.1927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234627/
https://www.ncbi.nlm.nih.gov/pubmed/35481940
http://dx.doi.org/10.1002/hep4.1927

Ejemplares similares